Monitor Q1 2027 for Phase 2 topline AD results and the Q4 2026 FDA Type B meeting outcome. The company's cash runway into Q3 2027 suggests a financing event may be needed before Phase 3 initiation, which could create dilution risk.
Price Chart
Executive Summary
Turn Therapeutics released an updated investor presentation on October 6, 2026, detailing progress across its pipeline including GX-03 for atopic dermatitis, onychomycosis, and hidradenitis suppurativa. The presentation highlights positive Phase 2 Stage 1 data and an optimized Stage 2 design for AD, with topline results expected Q1 2027. The company reported a cash balance of $10.3M as of June 30, 2026, with runway into Q3 2027, but notes that several upcoming milestones require additional capital.
Key Facts
- Phase 2 RCT for GX-03 in moderate-to-severe atopic dermatitis ongoing; topline results expected Q1 2027
- Stage 1 (N=50) completed June 2026; Stage 2 (N~135) currently enrolling with optimized design
- In the PP-NRS7 subgroup (N=25), GX-03 showed 61.5% vIGA-AD success vs 8.3% vehicle (p=0.0123) at Week 4
- GX-03 has been FDA cleared as non-cytotoxic, non-sensitizing and non-irritating; 200,000+ patients treated with zero reported adverse events
- Cash balance of $10.3M as of June 30, 2026; cash runway into Q3 2027
- ~29.8M common shares outstanding as of June 30, 2026
- FDA Type B meeting planned Q4 2026; Phase 3 initiation for AD expected mid-2027
- Onychomycosis program Phase 3 ready; Phase 2a for HS expected to initiate Q1 2027
- Sterile collagen powder out-licensed for $70M+ milestones
- 17 issued patents with coverage through 2040
Financial Impact
Cash balance of $10.3M with ~$1M/quarter G&A burn; runway into Q3 2027. Total money raised since inception ~$29M; accumulated deficit $29.2M. Additional capital required for upcoming clinical milestones.
Risk Factors
- Cash runway only into Q3 2027; additional capital needed for Phase 3 trials and other milestones
- Phase 2 topline results for AD not expected until Q1 2027; binary catalyst risk
- Stage 2 data based on small subgroup (N=25); results may not replicate in larger population
- Pre-revenue company with no approved products; depends on successful clinical development and regulatory approval
- Accumulated deficit of $29.2M against $10.3M cash
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-107329 |
| Document: ea0307911-8k_turn.htm | 0001213900-26-107329 |
| Document: 0001213900-26-107329-index-headers.html | 0001213900-26-107329 |
| Document: 0001213900-26-107329-index.html | 0001213900-26-107329 |
| Document: 0001213900-26-107329.txt | 0001213900-26-107329 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.61 (+1.34%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.61 (−12.31%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.61 (−20.70%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.61 (−22.84%) |
Aug 18, 2026 9w ago | 8-K | $9.99 | awaiting T+60 | — | $10.61 (+6.21%) |
Jul 7, 2026 15w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.61 (+9.27%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.61 (+76.25%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.61 (+67.61%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.61 (+100.57%) |
May 19, 2026 22w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.61 (+133.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers